A new Alzheimer’s drug is being hailed as the "beginning of the end" in a search for an effective treatment for the condition.
The drug - called lecanemab - was found to reduce memory decline among patients with early stages of the disease. This was found in a trial which involved 1,795 participants with early Alzheimer’s, with the drug slowing the disease progression by 27 percent compared with patients taking the placebo.
The study has been published in The New England Journal of Medicine, and experts are hailing it as long-awaited proof that Alzheimer’s disease can be treated.
The results were reported by Eisai, a Tokyo-based pharmaceutical company which has partnered with US biotech firm Biogen to develop lecanemab. “This trial is an important first step, and I truly believe it represents the beginning of the end,” said Professor John Hardy, group leader at the UK Dementia Research Institute at University College London.“The amyloid theory has been around for 30 years so this has been a long time coming.
Read more on dailyrecord.co.uk